Updated Price Disclosure Guidelines
Tuesday, 26 November, 2013
An updated version of the聽Price Disclosure Arrangements Procedural and Operational Guidelines for Expanded and Accelerated Price Disclosure聽has been published.
The updated Guidelines reflect changes made to the聽National Health (Pharmaceutical聽 Benefits) Regulations 1960聽in April 2013. According to the Department of Health website, those Regulation changes were made following December 2012 litigation concerning inclusion of de-listed brands in price disclosure calculations.聽 The Guidelines also provide more information about a number of other matters, including:
- how to disclose data when the commercial responsibility for a brand passes before the legally responsible person has been changed;
- calculating new premiums for price disclosure reductions;
- how price disclosure reductions are applied to new brands listing after the end of a data collection period and before the reduction day;
and
- how reduced prices are adjusted to take account of any change in pricing quantity for brands of a pharmaceutical item between the end of the data collection period and the reduction day
Find out more at聽
'Enhanced cleaning' cuts hospital-acquired infections by one-third
Australian researchers who introduced so-called 'enhanced cleaning' measures onto several...
Improving success rates: lactic acid in IVF
The co-author of research published in Biomolecules explains how the metabolism of the...
Hep C point-of-care test helps marginalised populations
A program using diagnostic technologies at the 'point of care' is helping combat...
